• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

AlzeCure Pharma

6.16 SEK-2.84 %10.7, 17.29
Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.84 %
+46.53 %
+376.85 %
+265.38 %
+251.67 %
+158.58 %
+43.76 %
-6.83 %
-25.72 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
849.45M SEK
Turnover
2.54M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26.8
2026

Interim report Q2'26

11.11
2026

Interim report Q3'26

23.2
2027

Annual report '26

Regulatory press release02.07.2026, 08.00

Final outcome of AlzeCure’s rights issue

AlzeCure Pharma
Regulatory press release01.07.2026, 07.00

AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project

AlzeCure Pharma
Regulatory press release29.06.2026, 17.30

Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release16.06.2026, 10.00

Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's

AlzeCure Pharma
Regulatory press release16.06.2026, 08.00

The subscription period in AlzeCure Pharma's Rights Issue begins today

AlzeCure Pharma
Press release10.06.2026, 12.58

Redeye: AlzeCure Pharma: From lab to Lilly – A historic USD1bn validation

AlzeCure Pharma
Regulatory press release09.06.2026, 07.10

AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project

AlzeCure Pharma
Regulatory press release05.06.2026, 08.00

AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document

AlzeCure Pharma
Regulatory press release26.05.2026, 08.00

NOTICE TO ANNUAL GENERAL MEETING IN AlzeCure Pharma AB

AlzeCure Pharma
Press release19.05.2026, 10.00

AlzeCure Pharma to host live seminar on the pain project TrkA-NAM ACD137 with a focus on osteoarthritis and neuropathic pain

AlzeCure Pharma
Press release13.05.2026, 12.00

AlzeCure Pharma to present at Redeye Investor Forum Online on May 21

AlzeCure Pharma
Press release13.05.2026, 10.00

AlzeCure Pharma to present at ABG Investor Days on May 21

AlzeCure Pharma
Press release08.05.2026, 10.16

Redeye: AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856

AlzeCure Pharma
Press release06.05.2026, 10.00

New scientific article published on TrkA-NAM ACD137 against osteoarthritic pain

AlzeCure Pharma
Regulatory press release05.05.2026, 08.00

AlzeCure publishes its interim report for January – March 2026

AlzeCure Pharma
Regulatory press release30.04.2026, 08.00

Adjusted timeline for the previously communicated rights issue

AlzeCure Pharma
Regulatory press release24.04.2026, 08.00

AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million

AlzeCure Pharma
Press release20.04.2026, 10.00

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

AlzeCure Pharma
Regulatory press release08.04.2026, 08.00

AlzeCure Pharma publishes its Annual Report for 2025

AlzeCure Pharma
Press release07.04.2026, 10.00

AlzeCure Pharma to present at Redeye Healthcare Day on April 14

AlzeCure Pharma